Earnings summaries and quarterly performance for Maze Therapeutics.
Research analysts covering Maze Therapeutics.
Recent press releases and 8-K filings for MAZE.
Maze Therapeutics Provides Pipeline Updates and Financial Outlook at J.P. Morgan Healthcare Conference
MAZE
Guidance Update
New Projects/Investments
- Maze Therapeutics expects to deliver top-line proof-of-concept data for MZE829 for APOL1-mediated kidney disease by the end of Q1 2026.
- The company plans to initiate its Phase 2 study for MZE782 in PKU by mid-2026 and its kidney disease program for MZE782 by the end of 2026.
- Maze Therapeutics has operating capital into 2028, which is sufficient to support all described near-term milestones and catalysts.
- MZE829 targets at least 250,000 individuals in the U.S. with APOL1-mediated kidney disease, with a goal of achieving at least a 30% reduction in UACR.
Jan 12, 2026, 4:15 PM
Maze Therapeutics Outlines Key Catalysts for MZE829 and MZE782 Programs
MAZE
Guidance Update
New Projects/Investments
- Maze Therapeutics is reiterating guidance to deliver top-line proof-of-concept data for MZE829 in APOL1 kidney disease by the end of Q1 2026, with positive results expected to initiate planning for a Phase IIB/III study.
- The company plans to initiate a Phase II study for MZE782 in PKU by the middle of 2026 and a Phase II study for MZE782 in chronic kidney disease by the end of 2026.
- Maze Therapeutics maintains a strong capital position, with operating capital secured into 2028, funding all described near-term milestones and catalysts.
Jan 12, 2026, 4:15 PM
Maze Therapeutics Provides Pipeline Updates and Financial Outlook
MAZE
Guidance Update
New Projects/Investments
- Maze Therapeutics reiterated its guidance to deliver top-line proof-of-concept data for MZE829 in APOL1-mediated kidney disease by the end of Q1 2026. Positive results would lead to planning for a Phase 2B3 study.
- The company announced plans to initiate its MZE782 PKU study by mid-2026 and its MZE782 kidney disease program study by the end of 2026.
- Maze Therapeutics reported a strong capital position, with operating capital secured into 2028, funding all near-term milestones and catalysts.
Jan 12, 2026, 4:15 PM
Maze Therapeutics Provides Pipeline Updates and Financial Runway
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics anticipates reporting topline Phase 2 proof-of-concept data for MZE829 in APOL1-mediated Kidney Disease (AMKD) by the end of Q1 2026.
- The company plans to initiate Phase 2 trials for MZE782 in Phenylketonuria (PKU) by mid-2026 and in Chronic Kidney Disease (CKD) in 2H 2026.
- As of September 30, 2025, Maze Therapeutics reported $383.9 million in cash, cash equivalents, and marketable securities, which is expected to provide operating capital into 2028 based on its current business plan.
Jan 12, 2026, 12:00 PM
Maze Therapeutics Reviews 2025 Accomplishments and Prepares for Key Q1 2026 Data Readout
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics achieved significant milestones in 2025, including going public, initiating the MZE829 study for APOL1 kidney disease, releasing additional data for its MZE782 program, and completing a small PIPE financing.
- The company anticipates data from its Horizon study for MZE829 in APOL1 kidney disease by the end of Q1 2026. This data is expected to show a 30% reduction in proteinuria (measured by UACR) in broad APOL1-mediated kidney disease (AMKD) patients, which would be considered clinically significant.
- MZE829 is differentiated from competitors, such as Vertex's inaxaplin, by its dual mechanism of action, which involves both blocking the pore and disrupting its assembly, whereas inaxaplin only blocks the pore.
- Following a successful MZE829 readout, Maze Therapeutics plans to initiate planning for a Phase 2b/3 study. Additionally, the company will begin two Phase 2 studies for its MZE782 program in 2026, building on positive data released in September.
Dec 3, 2025, 3:25 PM
Maze Therapeutics Discusses 2025 Accomplishments and Upcoming MZE829 Data Readout
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics experienced a transformative 2025, marked by going public, initiating its MZE829 study for APOL1 kidney disease, and presenting additional data for MZE782, supported by a PIPE financing.
- The company expects to deliver MZE829 Phase 2 data for APOL1 kidney disease by the end of Q1 2026, with a key target of demonstrating at least a 30% reduction in proteinuria (UACR) in broad AMKD patients.
- MZE829 is differentiated by its dual mechanism of blocking the APOL1 pore and disrupting its assembly, which is believed to offer greater potency compared to competitors.
- Following a successful MZE829 data readout, Maze plans to initiate planning for a Phase 2b/3 study, and also intends to start two Phase 2 studies for MZE782 in 2026 after positive data in September 2025.
Dec 3, 2025, 3:25 PM
Maze Therapeutics Reflects on 2025 Accomplishments and Outlines Key 2026 Objectives
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics experienced a transformative 2025, going public early in the year and initiating a study for MZE829 for APOL1 kidney disease.
- The company anticipates delivering data from its Phase 2 Horizon study for MZE829 (APOL1 kidney disease) by the end of Q1 2026. This study aims to demonstrate clinical proof of concept in broad AMKD patients (with or without diabetes) with a target of at least a 30% reduction in proteinuria (UACR).
- MZE829 is differentiated from competitors like Vertex's inaxaplin by its dual mechanism, which blocks the APOL1 pore and disrupts its assembly, leading to significant potency differentiation.
- In September 2025, Maze Therapeutics released additional data for its second program, MZE782, which was well-received and led to a small PIPE financing. The company plans to start two Phase 2 studies for MZE782 in 2026.
Dec 3, 2025, 3:25 PM
Maze Therapeutics Highlights Upcoming Clinical Milestones for MZE829 and MZE782 Programs
MAZE
New Projects/Investments
- Maze Therapeutics plans to deliver clinical proof of concept data for MZE829 in APOL1-mediated kidney disease (AMKD) in Q1 2026, aiming for a 30% reduction in uACR.
- The company intends to initiate two Phase II studies in 2026 for its MZE782 program: one for PKU and another for chronic kidney disease (CKD).
- In September, MZE782 demonstrated clinical proof of mechanism for PKU with a 40-fold increase in urinary Phe and for CKD by showing an eGFR dip indicative of renal protection.
- Maze Therapeutics is well capitalized to achieve its data catalysts, following a financing round in September.
Nov 20, 2025, 12:00 PM
Maze Therapeutics Outlines 2026 Clinical Milestones and Financial Position
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics is currently enrolling its Phase 2 study for MZE829 in APOL1-mediated kidney disease (AMKD) and anticipates releasing clinical proof of concept data in Q1 2026, with a target of achieving a 30% reduction in UACR.
- Building on strong proof of mechanism data from September 2025, the company plans to initiate two Phase 2 programs in 2026 for MZE782: one for Phenylketonuria (PKU) and another for chronic kidney disease (CKD).
- Maze Therapeutics is well-capitalized to deliver on its upcoming data catalysts, following a September 2025 financing.
Nov 20, 2025, 12:00 PM
Maze Therapeutics Provides Update on Kidney Disease Programs and Upcoming Milestones
MAZE
New Projects/Investments
Guidance Update
- Maze Therapeutics is developing small molecule precision medicines primarily focused on kidney disease, including APOL1-mediated kidney disease (AMKD).
- Their lead program, Maze 829, an APOL1 inhibitor for AMKD, is expected to have a Q1 2026 readout for clinical proof of concept in broad AMKD (with or without diabetes), targeting at least a 30% reduction in proteinuria. Maze 829 is differentiated by its dual mechanism (blocking the pore and disrupting its assembly) and preclinical potency advantage.
- The company also discussed progress on MAZE 782 (SLC6A19 inhibitor), which demonstrated best-in-class properties for Phenylketonuria (PKU) and an eGFR dip in healthy volunteers for Chronic Kidney Disease (CKD), indicative of renal protection.
- The potential market for AMKD is estimated at at least 250,000 individuals, comparable in size to the IGAN population.
Nov 13, 2025, 7:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more